In the U.S., the import prices of Amphotericin B are steadily moving upwards, propelled by straining supplies, increased logistics costs, and strong demand from the healthcare sector. The prices softened for a few initial months of this year due to excess inventory and advance imports. Presently, the market is back in a phase of strengthening prices. Disruptions at major overseas ports, increased time for shipment, and high container and handling charges have resulted in restricted supply flow, which in turn has increased the overall landed cost. The pressures are transmitted along the value chain, reinforcing upward price momentum. Institutions continue to secure their stocks in anticipation of a shortage, and therefore hospitals and healthcare distributors continue to have strong demand for the drug. Analysts expect this upward trend to continue shortly because freight congestion and supply-chain instability show little indication of improvement. Unless the global supply conditions see significant improvement, prices of Amphotericin B are likely to remain high, a factor that will drive stakeholders to plan their procurement strategy with care.
